Export financials
SeaSpine Holdings Corporation (SPNE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

SeaSpine Holdings Corporation Financial Statements 2021-2011 | SPNE
Annual Financial Statements SeaSpine Holdings Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
426 M | 515 M | 268 M | 236 M | 126 M | 79.6 M | 139 M | - | - | - | - |
Shares |
33.6 M | 27.2 M | 19 M | 15.4 M | 12.4 M | 11.2 M | 11 M | 11 M | 11 M | - | - |
Historical Prices |
12.7 | 18.9 | 14.1 | 15.3 | 10.1 | 7.09 | 12.6 | - | - | - | - |
Net Income |
-54.3 M | -43.2 M | -8.59 M | -9.53 M | -7.51 M | -9.77 M | -55.5 M | -24.5 M | -25.7 M | -30.4 M | - |
Revenue |
191 M | 154 M | 43.7 M | 38 M | 132 M | 129 M | 133 M | 139 M | 147 M | 148 M | - |
Cost of Revenue |
76.9 M | 56.8 M | 58 M | 56 M | - | - | - | - | - | - | - |
Gross Profit |
115 M | 97.5 M | 28.1 M | 23 M | 21.5 M | 19.1 M | 72.1 M | 82 M | 91.1 M | 92.7 M | - |
Operating Income |
-61 M | -43.4 M | -39.2 M | -33.1 M | -32.7 M | -43.5 M | -52.2 M | -20.3 M | -17.4 M | - | - |
Interest Expense |
5.53 M | 463 K | 302 K | -256 K | 430 K | -264 K | -877 K | -269 K | -4.56 M | - | - |
EBITDA |
-47 M | -32.7 M | -28.9 M | -22.4 M | -21.8 M | -31.7 M | -39.7 M | -7.39 M | -3.87 M | -14.4 M | - |
Operating Expenses |
- | 140 M | 135 M | 121 M | 113 M | 117 M | 124 M | 102 M | 108 M | 113 M | - |
General and Administrative Expenses |
42.9 M | 35.9 M | 33.6 M | 30.2 M | 97.3 M | 101 M | 111 M | 88.2 M | 93 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement SeaSpine Holdings Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 37 M | 36.8 M | 36.8 M | 36.6 M | 36.4 M | 33.5 M | 27.9 M | 27.7 M | 27.5 M | 27.3 M | 26.4 M | 19.1 M | 19.1 M | 18.9 M | 18.9 M | 18.7 M | 14.8 M | 14.6 M | 14.1 M | 13.5 M | 12.8 M | 11.9 M | 11.6 M | 11.3 M | 11.3 M | 11.2 M | 11.2 M | 11.1 M | 11.2 M | 11 M | 11 M | - | 11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | -15.5 M | -13.9 M | -16.6 M | - | -17.6 M | -5.21 M | -12.7 M | -10.3 M | -6.57 M | -13.7 M | -12.6 M | -8.59 M | -9.66 M | -12 M | -8.99 M | -9.53 M | -9.53 M | -7.36 M | -7.1 M | -7.51 M | -7.46 M | -8.04 M | -9.1 M | -9.77 M | -9.45 M | -12 M | -12 M | -13.8 M | -14.2 M | -17.7 M | -9.9 M | -8.24 M | -5.32 M | -5.43 M | -5.56 M | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | 67.1 M | 56.3 M | 50.7 M | - | 46.4 M | 47.5 M | 42 M | 46.4 M | 43.2 M | 28.6 M | 36.1 M | 43.7 M | 39.9 M | 39.3 M | 36.2 M | 38 M | 35.8 M | 36.4 M | 33.2 M | - | 31.7 M | 34.2 M | 31.9 M | - | 31.7 M | 33.2 M | 31.4 M | - | 32.7 M | 33.5 M | 32.3 M | - | 33.6 M | 35.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | 26.6 M | 19.1 M | 20.4 M | - | 18.3 M | 17.5 M | 15.4 M | - | 14.1 M | 11.7 M | 13.8 M | - | 14.4 M | 14.3 M | 13.6 M | - | 14.2 M | 14.6 M | 12.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 40.5 M | 37.2 M | 30.3 M | - | 28.2 M | 30 M | 26.6 M | 29.1 M | 29.1 M | 16.9 M | 22.3 M | 28.1 M | 25.5 M | 25 M | 22.6 M | 23 M | 21.6 M | 21.8 M | 21 M | 21.5 M | 19.6 M | 20.2 M | 18.7 M | 19.1 M | 17.9 M | 19.3 M | 17.1 M | 18.1 M | 15.3 M | 19 M | 19.7 M | 20.5 M | 19.3 M | 20.6 M | 21.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | -14.7 M | -14.5 M | -16.8 M | - | -18.3 M | -11.1 M | -12.5 M | - | -6.65 M | -13.7 M | -12.7 M | - | -9.34 M | -12 M | -9.04 M | - | -9.45 M | -7.17 M | -7.05 M | - | -7.73 M | -8.18 M | -9.09 M | - | -9.5 M | -12.2 M | -12.3 M | - | -14.7 M | -16.1 M | -8.32 M | - | -4.45 M | -5.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | -419 K | -559 K | 2 K | - | -231 K | 6.08 M | -159 K | - | 136 K | 14 K | 227 K | - | -97 K | -25 K | 73 K | - | -190 K | -157 K | 20 K | - | 215 K | 185 K | -13 K | - | -59 K | -232 K | 258 K | - | 195 K | -51 K | -721 K | - | -30 K | -22 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | -1.85 M | -6.04 M | -12.6 M | - | -7.99 M | -5.25 M | -9.79 M | - | 1.28 M | -8.48 M | -10.1 M | - | -1.41 M | -6.54 M | -6.27 M | - | -1.5 M | -1.9 M | -4.41 M | - | 450 K | -2.74 M | -6.38 M | - | -514 K | -5.93 M | -9.13 M | - | -14.4 M | -10.2 M | -5.31 M | - | 5.41 M | 2.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 14.8 M | 12.2 M | 10.9 M | - | 11.6 M | 9.99 M | 10.4 M | - | 8.91 M | 8.84 M | 8.55 M | - | 30.1 M | 27.6 M | 27.3 M | - | 27 M | 25.4 M | 24.5 M | - | 23.7 M | 24.2 M | 24 M | - | 23.8 M | 27 M | 25.4 M | - | 26.3 M | 31.7 M | 25.1 M | - | 20.3 M | 22.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Main types of financial statements SeaSpine Holdings Corporation SPNEFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting SeaSpine Holdings Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Venus Concept
VERO
|
- | - | $ 726 K | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B | ||
|
Viemed Healthcare
VMD
|
$ 8.81 | -2.87 % | $ 343 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
NuVasive
NUVA
|
- | - | $ 2.07 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
$ 139.95 | -3.71 % | $ 9.85 B | ||
|
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
TELA Bio
TELA
|
$ 0.78 | 2.43 % | $ 36.6 M | ||
|
Zynex
ZYXI
|
- | - | $ 21.1 M | ||
|
TransMedics Group
TMDX
|
$ 96.58 | 2.84 % | $ 3.28 B | ||
|
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
Butterfly Network
BFLY
|
$ 6.11 | 6.0 % | $ 1.51 B | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
Zimmer Biomet Holdings
ZBH
|
$ 103.42 | 1.3 % | $ 20.5 B | ||
|
Abbott Laboratories
ABT
|
$ 104.47 | -0.23 % | $ 182 B | ||
|
Align Technology
ALGN
|
$ 163.89 | 0.26 % | $ 11.9 B | ||
|
Alphatec Holdings
ATEC
|
$ 7.08 | 1.95 % | $ 1.06 B | ||
|
Boston Scientific Corporation
BSX
|
$ 43.66 | 1.45 % | $ 64.6 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 7.93 | 1.34 % | $ 578 M | ||
|
Aethlon Medical
AEMD
|
$ 5.05 | -0.59 % | $ 3.4 M | ||
|
Bio-Rad Laboratories
BIO
|
$ 369.72 | 3.22 % | $ 10.1 B | ||
|
Apyx Medical Corporation
APYX
|
$ 2.44 | -4.5 % | $ 100 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
CONMED Corporation
CNMD
|
$ 48.11 | -0.59 % | $ 1.49 B | ||
|
Establishment Labs Holdings
ESTA
|
$ 70.8 | 1.86 % | $ 2.1 B | ||
|
Medtronic PLC
MDT
|
$ 100.7 | -1.58 % | $ 129 B | ||
|
Myomo
MYO
|
$ 0.88 | -3.85 % | $ 36.8 M | ||
|
MiMedx Group
MDXG
|
$ 3.2 | 0.63 % | $ 473 M | ||
|
Delcath Systems
DCTH
|
$ 19.7 | 1.7 % | $ 706 M | ||
|
Electromed
ELMD
|
$ 23.59 | 1.99 % | $ 195 M | ||
|
Inogen
INGN
|
$ 5.58 | -1.85 % | $ 148 M | ||
|
Globus Medical
GMED
|
$ 70.5 | 0.73 % | $ 9.53 B | ||
|
Quanterix Corporation
QTRX
|
$ 2.07 | -27.62 % | $ 88.3 M | ||
|
IRadimed Corporation
IRMD
|
$ 82.34 | -1.33 % | $ 1.05 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.26 | -8.45 % | $ 16.8 M | ||
|
ClearPoint Neuro
CLPT
|
$ 7.77 | -1.21 % | $ 220 M | ||
|
Accuray Incorporated
ARAY
|
$ 2.49 | 2.05 % | $ 305 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
AxoGen
AXGN
|
$ 56.98 | 2.9 % | $ 2.62 B |